<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02668510</url>
  </required_header>
  <id_info>
    <org_study_id>16/03</org_study_id>
    <nct_id>NCT02668510</nct_id>
  </id_info>
  <brief_title>RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort</brief_title>
  <official_title>A Randomized Controlled Pilot Trial Comparing Extracorporeal Shock Wave Therapy With Platelet Rich Plasma Versus Extracorporeal Shock Wave Therapy in a High Demand Cohort With Resistant Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Army Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Controlled Pilot Trial Comparing Extracorporeal Shock Wave Therapy with Platelet
      Rich Plasma versus Extracorporeal Shock Wave Therapy in a High Demand Cohort with Resistant
      Plantar Fasciitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this proposal is to perform a high-quality pilot study testing the efficacy of
      ESWT in combination with PRP for the management of resistant plantar fasciitis. We endeavor
      to determine if the pilot evidence supports a large, randomized study; and to conduct a power
      analysis for the follow-on study. The proposed pilot study will be a prospective
      double-blinded randomized controlled trial comparing pain and functionality at the 3 week, 6
      week, 12 week and 6 month marks between extracorporeal shock wave therapy (ESWT) with
      platelet rich plasma (PRP) injection versus extracorporeal shock wave therapy with placebo
      injection of normal saline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS)</measure>
    <time_frame>3, 6, 12, 24 weeks</time_frame>
    <description>Decreased first step pain over time with single treatment of ESWT &amp; PRP as measured by the VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Ankle Ability Measure (FAAM)</measure>
    <time_frame>3, 6, 12, 24 weeks</time_frame>
    <description>functionality scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Ankle Ability Measure extended sports scale</measure>
    <time_frame>3, 6, 12, 24 weeks</time_frame>
    <description>sports subscale for sport related activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>return to activity</measure>
    <time_frame>3, 6, 12, 24 weeks</time_frame>
    <description>achieving minimal clinical important difference (MCID) on FAAM sport scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeat treatment threshold</measure>
    <time_frame>3, 6, 12, 24 weeks</time_frame>
    <description>Decreased need for repeat ESWT as proven by achieving MCID on FAAM</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fasciitis, Plantar</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma Injection Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo injection group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>shockwave therapy with placebo normal saline injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>platelet rich plasma</intervention_name>
    <description>immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous</description>
    <arm_group_label>Platelet Rich Plasma Injection Group</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>placebo injection of normal saline immediately following shockwave therapy</description>
    <arm_group_label>Placebo injection group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Patients that are already selected for ESWT for the treatment of resistant plantar
             fasciitis as part of clinical care under the doctor-patient relationship

          -  X-ray imaging studies (Plain radiographs) documenting no additional sources for heel
             pain within 12 months(all x-rays were conducted as part of standard of care and no
             radiation will be specific to the research study)

          -  Active Duty Soldier as they are a high demand cohort with increased frequency of
             plantar fasciitis compared to the general population as outlined by Scher et al.

          -  Previously tried conservative management meeting referral to Orthopaedics: Pain
             medications, taping, orthoses, night splinting or physical therapy

          -  Body Mass Index (BMI) &lt;40kg/m2

        Exclusion Criteria:

          -  â€¢ History of trauma* or previous injury to heel requiring operative intervention

               -  All Soldiers pending medical board evaluation or punitive action

               -  History of connective tissue disorder (e.g., Marfan's Syndrome, Ehlers-Danlos
                  disease, Rheumatoid Arthritis, etc.)

               -  Leaving the geographical area permanently or for extended periods of time forcing
                  loss to follow up

               -  Treatment for plantar fasciitis with injection within the last 6 months

               -  Surgical indication or internal derangement of the foot

               -  Chronic pain conditions

               -  Pregnancy

               -  Tarsal tunnel syndrome

               -  Baxter's neuritis

               -  Rigid flat foot

               -  Active infection of the Foot overlying the injection area

               -  Use of immunomodulators, immunosuppressives, or chemotherapeutic agents

               -  Allergy or hypersensitivity to any of the proposed treatment medications

               -  Any other clinically significant acute or chronic medical conditions (e.g.,
                  bleeding disorder) that, in the judgment of the Investigator, would preclude the
                  use of a PRP or that could compromise patient safety, limit the patient's ability
                  to complete the study, and/or compromise the objectives of the study.

                    -  Trauma for this research study is defined as a specific event or mechanism
                       of injury, such as a direct blow or twisting injury of the foot that
                       initiated the onset of heel pain. The insidious onset of heel pain with
                       prolonged running or other physical activity is not defined as a traumatic
                       event.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy B Pekari, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>WBAMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amanda L Allen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WBAMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lola Norton</last_name>
    <role>Study Director</role>
    <affiliation>WBAMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy B Pekari, DSc</last_name>
    <phone>9157421693</phone>
    <email>timothy.b.pekari.mil@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justin D Orr, MD</last_name>
    <phone>9157421693</phone>
    <email>justin.d.orr.mil@mail.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Beaumont Army Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lola Norton</last_name>
      <phone>915-742-0993</phone>
      <email>lola.norton@us.army.mil</email>
    </contact>
    <contact_backup>
      <last_name>Arturo Alvarez</last_name>
      <phone>915-742-6075</phone>
      <email>Arturo.AlvarezIII@us.army.mil</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ogden JA, Cross GL, Williams SS. Bilateral chronic proximal plantar fasciopathy: treatment with electrohydraulic orthotripsy. Foot Ankle Int. 2004 May;25(5):298-302.</citation>
    <PMID>15134609</PMID>
  </reference>
  <reference>
    <citation>Chew KT, Leong D, Lin CY, Lim KK, Tan B. Comparison of autologous conditioned plasma injection, extracorporeal shockwave therapy, and conventional treatment for plantar fasciitis: a randomized trial. PM R. 2013 Dec;5(12):1035-43. doi: 10.1016/j.pmrj.2013.08.590. Epub 2013 Aug 22.</citation>
    <PMID>23973504</PMID>
  </reference>
  <reference>
    <citation>Aqil A, Siddiqui MR, Solan M, Redfern DJ, Gulati V, Cobb JP. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. Clin Orthop Relat Res. 2013 Nov;471(11):3645-52. doi: 10.1007/s11999-013-3132-2. Epub 2013 Jun 28. Review.</citation>
    <PMID>23813184</PMID>
  </reference>
  <reference>
    <citation>Martin RL, Irrgang JJ, Burdett RG, Conti SF, Van Swearingen JM. Evidence of validity for the Foot and Ankle Ability Measure (FAAM). Foot Ankle Int. 2005 Nov;26(11):968-83.</citation>
    <PMID>16309613</PMID>
  </reference>
  <reference>
    <citation>Metzner G, Dohnalek C, Aigner E. High-energy Extracorporeal Shock-Wave Therapy (ESWT) for the treatment of chronic plantar fasciitis. Foot Ankle Int. 2010 Sep;31(9):790-6. doi: 10.3113/FAI.2010.0790.</citation>
    <PMID>20880482</PMID>
  </reference>
  <reference>
    <citation>Yin MC, Ye J, Yao M, Cui XJ, Xia Y, Shen QX, Tong ZY, Wu XQ, Ma JM, Mo W. Is extracorporeal shock wave therapy clinical efficacy for relief of chronic, recalcitrant plantar fasciitis? A systematic review and meta-analysis of randomized placebo or active-treatment controlled trials. Arch Phys Med Rehabil. 2014 Aug;95(8):1585-93. doi: 10.1016/j.apmr.2014.01.033. Epub 2014 Mar 21. Review.</citation>
    <PMID>24662810</PMID>
  </reference>
  <reference>
    <citation>de Mos M, van der Windt AE, Jahr H, van Schie HT, Weinans H, Verhaar JA, van Osch GJ. Can platelet-rich plasma enhance tendon repair? A cell culture study. Am J Sports Med. 2008 Jun;36(6):1171-8. doi: 10.1177/0363546508314430. Epub 2008 Mar 7.</citation>
    <PMID>18326832</PMID>
  </reference>
  <reference>
    <citation>O'Malley MJ, Vosseller JT, Gu Y. Successful use of platelet-rich plasma for chronic plantar fasciitis. HSS J. 2013 Jul;9(2):129-33. doi: 10.1007/s11420-012-9321-9. Epub 2013 May 18.</citation>
    <PMID>24426857</PMID>
  </reference>
  <reference>
    <citation>Ang TW. The effectiveness of corticosteroid injection in the treatment of plantar fasciitis. Singapore Med J. 2015 Aug;56(8):423-32. doi: 10.11622/smedj.2015118. Review.</citation>
    <PMID>26311907</PMID>
  </reference>
  <reference>
    <citation>Scher DL, Belmont PJ Jr, Bear R, Mountcastle SB, Orr JD, Owens BD. The incidence of plantar fasciitis in the United States military. J Bone Joint Surg Am. 2009 Dec;91(12):2867-72. doi: 10.2106/JBJS.I.00257.</citation>
    <PMID>19952249</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heel Pain</keyword>
  <keyword>extracorporeal shock wave therapy</keyword>
  <keyword>ESWT</keyword>
  <keyword>shock wave</keyword>
  <keyword>Soldiers</keyword>
  <keyword>Platelet rich plasma</keyword>
  <keyword>PRP</keyword>
  <keyword>Autologous conditioned plasma</keyword>
  <keyword>Military</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

